Cytomegalovirus-induced salivary gland pathology: AREG, FGF8, TNF-α, and IL-6 signal dysregulation and neoplasia

Michael Melnick a,⁎, Krysta A. Deluca a, Parish P. Sedghizadeh b, Tina Jaskoll a

a Laboratory for Developmental Genetics, USC, USA
b Oral and Maxillofacial Pathology, Division of Diagnostic Sciences, USC, 925 W 34th Street, Los Angeles, CA, 90089-0641 USA

A R T I C L E   I N F O

Keywords:
Cytomegalovirus
CMV-induced pathology
Salivary gland
AREG
FGF8
IL-6
TNF-α

A B S T R A C T

Mucoepidermoid carcinoma (MEC) is the most common malignant tumor originating in major and minor salivary glands (SGs). Although the precise multifactorial etiology of human SG-MEC is largely unknown, we have recently shown that cytomegalovirus (CMV) is an important component of MEC tumorigenesis. Despite the well-documented overexpression of the EGFR → ERK signaling pathway in SG-MEC, there has been limited to no clinical success with inhibition of this pathway. Using our previously characterized mouse model of CMV-induced SG dysplasia/neoplasia, we report that inhibitors of the EGFR → ERK pathway do not ameliorate or rescue well-established pathology, either singly or in combination, but they do inhibit the evolution of progressive pathogenesis (“disease tolerance”) in the face of mounting CMV burden. Failure to rescue SG pathology, suggested a possible increase in the ligand levels of alternative pathways that share cell proliferation and survival effectors (e.g. ERK and PI3K). Here we present evidence of a highly significant upregulation of ligands for the EGFR, FGFR, IL-6R, and TNFR signaling pathways, all of which converge upon the Raf/MEK/ERK amplification module. This explains our finding that even in the presence of the highest nontoxic dose of an ERK phosphorylation inhibitor, pERK is undiminished. Given the considerable pathway crosstalk, a deep understanding of subversion and dysregulation of the SG interactome by CMV is a priori quite daunting. Circumventing this dilemma, we present evidence that concurrent inhibition of ERK phosphorylation (U0126) and CMV replication (acyclovir) obviates progressive pathogenesis and results in complete SG rescue (tumor regression). These findings provide a mechanistic foundation for potential clinical trials that utilize similar concurrent treatment with extant FDA-approved drugs.

© 2013 Elsevier Inc. All rights reserved.

Introduction

Human cytomegalovirus (hCMV) is common, 50–90% of adults being seropositive, depending on geographical location and socioeconomical status (Boppana and Fowler, 2007). Like other DNA herpes viruses, hCMV establishes lifelong persistence and latent infection following primary exposure; the precise triggering mechanisms that promote hCMV reactivation in immunocompetent persons are unknown (Yuan et al., 2009). Of special interest, hCMV, both active and latent, has a particular tropism for salivary glands (Nichols and Boeckh, 2000; Wagner et al., 1996).

We have recently confirmed that hCMV is a principle element in the multifactorial causation of salivary gland (SG) mucoepidermoid carcinoma (MEC) (Melnick et al., 2012). Active hCMV protein expression positively correlates with over 90% of SG-MEC tumor cases; active hCMV also correlates and colocalizes with upregulation and activation of an established oncogenic signaling pathway (COX/AREG/EGFR/ERK).

That human SG-MEC is a virally implicated pathology, is further supported by our finding that purified mouse CMV (mCMV) induces cellular pathology in an in vitro mouse SG organ model that displays a number of histologic and molecular characteristics similar to human MEC (Jaskoll et al., 2011; Melnick et al., 2011). Specifically, we have demonstrated that mCMV induces (1) mesenchymal-to-epithelial transformation (MET); (2) epithelial and mesenchymal hyperplasia, dysplasia and neoplasia; (3) loss of basement membrane zone components, reduced expression of epithelial-specific adherens junction proteins (E-cadherin, p120), and admixing of stromal-derived and epithelial-derived cells; (4) expression of CRTC1 protein, a protein found in SG MECs but not in normal SG tissue (Tirado et al, 2007); and (5) upregulation of the activated COX/AREG/EGFR/ERK signaling pathway. Further, the neoplastic phenotype is initially ameliorated by treatment with small molecule inhibitors of several key targets in the autocrine loop; inhibition of ERK phosphorylation completely precluded pathology, but less so with inhibitors of COX or EGFR. This suggested that other receptor tyrosine kinases mediating signals...
that converge downstream on ERK are also likely to play a key role in SG tumorigenesis (e.g. FGFR).

Since CMV and other viruses commonly hijack host cell molecular networks for self-propagation, eliciting concomitant cellular pathology, obvious questions remain. Among these are: Given the widespread resistance to anticancer kinase inhibitors (Engelman and Settleman, 2008; Wilson et al., 2012), can inhibitors of EGFR and ERK phosphorylation ameliorate or rescue well-established mouse SG pathology? Given that virally implicated pathology is routinely associated with perturbations to multiple host signaling pathways (Gulbahce et al., 2012; Rozenblatt-Rosen et al., 2012), what additional pathways might be dysregulated by mouse CMV proteins?

To address these questions, we have designed a series of mechanistic experiments and report that inhibitors of the EGFR → ERK pathway do not ameliorate or rescue well-established pathology, either singly or in combination, but they do inhibit the evolution of progressive pathogenesis, a sort of “disease tolerance” in the face of mounting CMV burden (Medzhitov et al., 2012). Further, complete rescue with an antiviral nucleoside analogue, acyclovir, in combination with a kinase inhibitor, indicates that mCMV replication is necessary to maintain SG pathogenesis. In this regard, mCMV-associated kinase inhibitor resistance appears to be related to increased expression and activation of the targeted kinase (ERK), along with the dysregulation of alternative signaling pathways that promote downstream cell proliferation and survival. Transcriptional analysis identified several of these dysregulated host cell pathways in addition to EGFR → ERK: FGF8, IL-6, TNF-α. All four growth factors and cytokines are primarily localized to the abnormally abundant stroma and its resident dysplastic/neoplastic fibroblasts. Targeting this enabling microenvironment may have therapeutic importance.

Materials and methods

Animals

Timed pregnant inbred C57/BL6 female mice (Charles River, Wilmington, MA) were purchased from Charles River (Wilmington, MA) and newborn (NB) mice were harvested as previously described (Melnick et al., 2006). Antibodies: pERK1/2 (Thr202/Tyr204); Amphiregulin; and IL-6 (M-19) (Santa Cruz Biotechnology). Data was quantitated using the Imagej image analysis software (NIH) and normalized to the level of β-actin expression in each sample.

Statistical analysis

Significant differences between mCMV-infected and control SMGs, as well as between mCMV and mCMV + treatment SMGs, were determined by student t-test, with α = 0.05 and the null hypothesis of R = 1. The calculated expression ratios (Rs) were log or arcsin transformed prior to analysis.

Western blot analysis

Newborn (NB) SMGs cultured for 6 (NB + 6) or 12 (NB + 12) days, were infected with 1×10⁵ PFU/ml of mCMV for 24 h and in control medium for the remaining culture period; controls consisted of SMGs cultured in control medium for the entire period. Data was quantitated using the Imagej image analysis software (NIH) and normalized to the level of β-actin expression in each sample.
the EGF→ERK pathway: NB SMG organs were infected with 1×10^5 PFU/ml mCMV for 24 h and cultured control medium until day 6. Beginning on day 6, explants were cultured in the presence or absence of 10 μM GEF + 10 μM U1026 (D6GEF + D6U) for an additional 8 days, a total of 14 days in culture (NB + 14). (3) Inhibition of CMV replication: To inhibit CMV replication, we used 10 μg/ml acyclovir sodium (American Pharmaceutical Partners, Inc, Schaumberg, IL), a synthetic purine nucleoside analogue which is a highly selective agent for CMV with low toxicity to the host cell (Burns et al., 1981) and previously shown to inhibit mCMV infection in mouse SMGs in vitro (Melnick et al., 2006); this concentration was previously shown to be the optimal, nontoxic dose (Melnick et al., 2006). NB SMG organs were infected with 1×10^5 PFU/ml mCMV for 24 h and cultured in control medium until day 6. Beginning on day 6, mCMV-infected SMGs were cultured in the presence 10 μg/ml acyclovir, 10 μM U0126 + 10 μg/ml acyclovir, 10 μM GEF + 10 μg/ml acyclovir or no drugs for an additional 8 days, a total of 14 days in culture (NB + 14). Controls consisted of uninfected SMGs without treatment or with D6GEF, D6U0126, or D6Acy treatment ( singly or in combination) cultured for 14 days. No differences were seen between untreated and inhibitor-treated uninfected SMGs; untreated controls are presented. In all experiments, media was changed daily and treatments (GEF, GEF+U0126, or U0126 with/without acyclovir) were added daily beginning on day 6.

Quantitative RT-PCR

For analysis of gene expression, qRT-PCR was conducted as previously described (Melnick et al., 2006, 2009) on NB + 6 control and mCMV-infected samples; each sample consisted of 4–5 pooled explants. RNA was extracted and 1μg RNA was reverse transcribed into first strand cDNA using ReactionReady™ First Strand cDNA Synthesis Kit: C-01 for reverse transcription (SABiosciences, Frederick, MD). The primer sets used were prevalidated to give single amplicons and purchased from SABiosciences (Frederick, MD); Areg (PPM02976A); Edf (PPM03703A); Fgf8 (PM02962A); I6 (PPM03015A); Tnfa (PPM03113A). Primers were used at concentration of 0.4 μM. The cycling parameters were 95 °C, 15 min; 40 cycles of 95 °C, 15 s; 55 °C, 30 s and 72 °C, 40 s. Specificity of the reactions was determined by subsequent melting curve analysis. RT-PCRs of RNA (not reverse transcribed) were used as negative controls. GAPDH was used to control for equal cDNA inputs and the levels of PCR product were expressed as a function of GAPDH. The relative fold changes of gene expression between the gene of interest and GAPDH, or between the NB + 6 control and mCMV-infected samples, were calculated by the 2-ΔΔCT method. Significant expression differences between mCMV-infected and control samples were determined by student t-test, with α = 0.01 and the null hypothesis of R = 1, where R is the mean relative expression ration (mCMV/control) across the entire sample. Expression ratios were log transformed prior to analysis to satisfy the assumption of normality.

Probabilistic neural network (PNN) analysis

We used PNN analyses to determine the contribution of each individual gene to the discrimination between experimental groups with 100% sensitivity and specificity (Melnick et al., 20011). As such, PNN analyses identify the relative importance (0–1, with 0 being of no relative importance and 1 being relatively most important) of specific gene expression changes that discriminate between phenotypes. It is the contextual change in expression, not the direction of change, which is important in defining the molecular phenotype. The foundational algorithm we used is based upon the work of Specht and colleagues (Chen, 1996; Specht, 1988; Specht and Shapiro, 1991). The proprietary software designed by Ward Systems Group (Frederick, MD) formulates Specht's procedure around a genetic algorithm (Goldberg, 1989).

Results

The trajectory of this research is to identify molecular targets that may prove critical to a therapeutic solution. To this end, one has always to discern patterns of covarying molecular and histopathologic phenotypes, relating measurements and localization of transcripts and proteins (input) to a well-characterized pathologic phenotype (output). Here we utilize an in vitro 3D submandibular gland (SMG) organ culture strategy previously shown to induce cellular pathology resembling secretory gland neoplasia (Jaskoll et al., 2011; Melnick et al., 2006, 2011).

Progressive histopathology

Newborn (NB) mouse SMGs are cultured in 1×10^5 PFU/ml mCMV for 24 h and maintained in control medium for a total of 6 or 12 days; controls consist of NB SMGs cultured for identical periods in control medium. Our novel 3D SMG organ culture system maintains the morphological integrity, 3D architecture and microenvironment seen in vivo SMGs. As we have previously reported (Melnick et al., 2011) and replicate here (Fig. 1), mCMV infection induces a severe cytotoxic effect (CPE), one which becomes progressively more severe in the period from 6 to 12 days in culture. Control SMGs on days 6 and 12 are characterized by densely packed, branched, cuboidal epithelia; these acini and ducts are embedded in a sparse fibromyxoid stroma containing variable numbers of stellate to ovoid fibroblasts (Figs. 1A, C). mCMV-infected SMGs cultured for 6 days (NB + 6) are characterized by a marked diminution of branching epithelia, acini and ducts; abnormal duct epithelia is hypoplastic and pseudo-stratified and the lumina are dilated and filled with cellular debris (Fig. 1B). These dysplastic epithelial components are embedded in a substantial, hypercellular stroma primarily composed of giant basophilic round cells mixed with far fewer and smaller eosinophilic cells (Fig. 1B).

mCMV-infected SMGs cultured for 12 days (NB + 12) exhibit a more severe viral CPE in the stroma, and abnormal parenchyma consistent with a tumorigenic phenotype (Fig. 1D). The marked increased stromal cellularity is composed of sheets of large basophilic, pleomorphic cells and smaller eosinophilic cells with high nuclear-to-cytoplasm ratios, prominent nuclei and nucleoli, and frequent kidney-shaped nuclei pathognomonic of CMV infection (Alwina, 2012). The increasingly sparse branched epithelia frequently display severely dilated lumina, and individual cells with increased nuclear-to-cytoplasmic ratios, hyperchromatism, and visible nucleoli. Intraluminal and extrabasal proliferation of epithelial cells is often seen, imparting a multilayered appearance to these epithelial islands. Further, a spectrum of...
morphotypes, from dysplastic to *in situ* to invasive, can be seen in the abnormal epithelia. Finally, pyknotic, karyorrhectic and karyolytic debris is often seen in the lumina of epithelial islands.

**pERK expression, viral distribution and inhibition**

Previously we reported that upregulation of ERK phosphorylation (pERK) is necessary for initial mCMV-induced pathogenesis (Melnick et al., 2011). Here we confirm that mCMV infection induces a notable increase in pERK expression in NB + 6 and NB + 12 SMGs compared to uninfected controls (Fig. 1; compare F to E and H to G). pERK is immunolocalized almost entirely to cytomicelial stromal cells and is difficult to detect in controls. With mCMV infection, Western blot analysis reveals a significant 40% increase in NB + 6 SMGs (p < 0.05) and a significant 50% increase in NB + 12 SMGs (p < 0.01) as compared to uninfected controls (Figs. 1.1, J). This increase is not significantly greater on day 12 than on day 6 (p > 0.50).

The importance of upregulated EGFR→ERK signaling to CMV-induced SG tumorigenesis has been demonstrated in humans and mice (Melnick et al., 2011, 2012). Thus, the EGFR→ERK pathway would seem the most parsimonious first target for drug-mediated SG tumor regression. To date, however, EGFR inhibitors have proven largely ineffective for human SG tumors (Bell and Hanna, 2012; Gillespie et al., 2012).

The input signal coming from activated EGFR proceeds through activated SOS and Ras. As a functional unit, the ERK pathway resembles a negative feedback amplifier (NFA) with an amplifier consisting of a three-tiered kinase module Raf-MEK-ERK and feedbacks emanating from ERK to SOS and Raf activation; the ratio of protein abundances of Raf, MEK and ERK is about 1:3:6 (Sturm et al., 2010). The remarkable design principles of the NFA recapitulates that they were often used in electronic circuits to confer robustness, output stabilization, and linearization of nonlinear signal amplification (Sturm et al., 2010). As expected, these properties are determinative of activation kinetics and drug (small molecule inhibitor) response, positive and negative. Here in NB + 6 SMGs with well-established mCMV-induced pathology, we utilized an EGFR inhibitor (gefitinib/GEF) or an inhibitor of MEK-mediated, ERK phosphorylation (U0126) to attempt to rescue the abnormal gland.

NB SMG organs were infected with 1×10⁵ PFU/ml mCMV for 24 h and then cultured in control medium to day 6; beginning on day 6, NB SMG organs were then cultured in control medium with or without 10 μM GEF or 10 μM U0126 for an additional 8 days, for a total of 14 days in culture (NB + 14). Other than the near absence of ductal dilation, the histopathology was similar to SMGs treated beginning on day 6 with U0126 alone (compare Fig. 3) to G, and the pERK expression and mCMV burden are comparable (compare Fig. 2K to H and L to I).

Finally, regardless of treatment (GEF, U0126, GEF + U0126), pERK immunolocalization in NB + 14 SMGs is only marginally different from one another, and from untreated mCMV-infected NB + 14 SMGs (Figs. 2B, E, H, K), i.e. pERK expression is marked and the protein is immunolocalized primarily to an abnormal stroma with high mCMV burden (Figs. 2C, F, I, L). This strongly suggests that other mediators whose signals converge downstream on the ERK pathway are at play.

**Dysregulation of ligands associated with multifunctional pathways**

Wilson et al. (2012) report that an increase in the ligand levels of alternative pathways that share cell proliferation and survival effectors (ERK and PI3K) confers resistance to inhibitors of an “oncogenic” kinase with a similar signaling output. In selecting other multifunctional pathways to investigate, we were cognizant that the parallels between organogenesis and tumorigenesis are ever more apparent (e.g. Becker et al., 2012). Functional studies in our laboratory and elsewhere have demonstrated that SMG organogenesis is regulated through interconnected growth factor and cytokine mediated multifunctional signaling pathways, many of which converge downstream on ERK and PI3K (Jaskoll and Melnick, 1999; Jaskoll et al., 2002, 2004; Kashimata et al., 2000; Melnick and Jaskoll, 2000; Melnick et al., 2001a,b,c). The hub of this complex network of parallel and broadly related pathways is NH-β (Melnick et al., 2001b).

In the present studies, we employed real-time quantitative PCR (qRT-PCR) to determine mCMV-induced transcriptional changes in a group of ligands mediating cognate ERK signaling pathways (EGFR, FGFR, IL-6R, TNGR) (Fig. 3). We performed qRT-PCR on NB + 6 control (n = 6) and mCMV-infected (n = 6) SMG samples; each sample consisted of 3–4 pooled explants. Both groups were compared to the starting explants (NB + 0), and these relative expression ratios (R) were compared to each other (Table 1). R is the mean increase or decrease in gland gene expression in NB + 6 uninfected or mCMV-infected glands compared to the starting glands (NB + 0). The variation of R is calculated as gene expression noise (σ): the value of σ (0 to 1) reflects fluctuations in levels of promoter-binding, transcription factor abundance, post-transcriptional modifications, etc. (Raser and O’Shea, 2005). Of the 6 ERK pathway ligand genes measured, 5 exhibited statistically significant expression differences between untreated and mCMV-infected NB + 6 SMG explants. mCMV infection had no effect on Egf expression, downregulated Tgf-a expression, and upregulated Areg (4-fold), FgfrB (5-fold), Il-6 (64-fold), and Tnfα (2-fold) expression. All four upregulated cognate proteins are immunolocalized primarily to the abnormally abundant, hypercellular stroma of mCMV-infected SMGs (Figs. 4B, D, F, H). These findings are expositive of those seen with attempted inhibition of MEK-mediated, ERK phosphorylation (Fig. 2).

Finally, we utilized probabilistic neural network (PNN) analyses to identify the relative importance (0–1, with 0 being of no relative importance and 1 being relatively most important) of specific gene expression changes to the mCMV-induced pathologic SMG phenotype. Our unbiased optimization algorithm reveals that with the transcript level of just these 4 genes (*Areg, Fgf8, Il-6, Tnfα*) NB + 6 SMGs can be classified as mCMV-infected or not with 100% sensitivity and 100% specificity (no false negatives; no false positives) (Fig. 4I). Interestingly, *Fgf8* and *Il-6* transcript levels are relatively much more important than *Areg* and *Tnfα* in the unbiased classification of pathology.

**mCMV replication and progressive pathogenesis**

We previously found that completion of the viral replication cycle beyond DNA replication is critical to the initiation of SMG pathogenesis
Here we investigated the question of whether mCMV replication is necessary for progressive pathogenesis with or without the presence of the EGFR → ERK pathway inhibitors. To answer this question, we utilized acyclovir, an antiviral nucleotide active against mCMV (Burns et al., 1981).

NB SMGs were infected with 1×10⁵ PFU/ml mCMV for 24 h and then cultured in control medium to day 6, allowing for several viral replication cycles; NB + 6 SMGs were then cultured in control medium with or without 10 μg/ml acyclovir, with or without EGFR → ERK pathway inhibitor, U0126 (or GEF, not shown), for an additional 8 days (a total of 14 days in culture). At NB + 14, explants treated with acyclovir show evident inhibition of mCMV replication (compare Fig. 5I to F); concomitantly, the SMGs are histologically nearing normal with increased epithelial branching, fewer dilations, and greatly reduced abnormal stroma (compare Fig. 5G to A); pERK expression is similar to that seen in controls and markedly less than in untreated mCMV-infected SMGs (Melnick et al., 2006, 2011).
NB+6 mCMV-infected SMGs concurrently treated with 10 μM U0126 and acyclovir for an additional 8 days (a total of 14 days in culture) show a normal SMG phenotype with considerable epithelial branching, a sparse fibromyxoid stroma, and no evidence of viral CPE (compare Fig. 5J to A) or viral presence (compare Fig. 5L to C, F). pERK expression is similar to that seen in controls (compare Fig. 5K to B). This completely rescued phenotype markedly differs from that seen with U0126 treatment alone (compare Figs. 5J–L to 2G–I); the U0126-treated, mCMV-infected SMGs exhibit some phenotypic improvement compared to untreated, mCMV-infected SMGs (compare Fig. 2G to A, 5D), but are still characterized by abnormal stroma and epithelia (compare Fig. 2G to 5J), increased pERK immunostaining (compare Fig. 2H to 5K) and considerable mCMV expression (compare Fig. 2I to 5L). These results indicate that persistent mCMV replication is necessary to maintain the viral cytopathic effect. Additionally, the need to further inhibit ERK phosphorylation (Figs. 5J–L) suggests that, even in the near absence of viral replication (Figs. 5I, L), there remains sufficient cellular memory (see Jullien and Gurdon, 2005) to preclude total elimination of stromal pathology (compare Fig. 5G to J) by day 14 in culture.

Discussion

Mucopidermoid carcinoma (MEC) is the most common malignant tumor originating in major and minor salivary glands, accounting for almost one-third of all SG carcinomas (Lujan et al., 2010;...
Schwarz et al., 2011). Although the precise etiology of MEC is largely unknown, we have recently shown that cytomegalovirus is an important component of MEC tumorigenesis (Melnick et al., 2011, 2012). Despite the well-documented overexpression of the EGFR→ERK signaling pathway in MEC (Akrish et al., 2009; Ito et al., 2009; Lujan et al., 2010), there has been limited to no success with inhibition of this pathway (Bell and Hanna, 2012; Gillespie et al., 2012), not unlike that seen with other malignancies (Engelman and Settleman, 2008). Using our previously described mouse model of CMV-induced SG dysplasia/neoplasia (Jaskoll et al., 2011; Melnick et al., 2011), we provide evidence that concurrent inhibition of ERK phosphorylation and inhibition of CMV replication obviates progressive pathogenesis and results in complete SG rescue (regression). These findings provide a mechanistic foundation for clinical trials that utilize similar concurrent treatment with extant FDA-approved drugs.

CMV has evolved numerous strategies to co-opt and alter host cell signaling networks for the purpose of propagating ever more virus (Sanchez and Spector, 2008; Schleiss, 2011). Cells respond to environmental challenges such as viral infection by reconfiguring regulated gene expression either by slow transcriptional adaptation or rapid post-transcriptional adaptation (Chalancq et al., 2012). Given the considerable crosstalk and redundancy in mammalian host cells, and the multifunctional pathways mediated by single molecular components, a deep understanding of the subversion and dysregulation of the SMG interactome by CMV is a priori quite daunting (Guibahce et al., 2012). For example, all the distinct ways in which mere 10 heterogeneous proteins can interact can be calculated as Bell's number (Bn), which in this case is 1.16×10^5 (Koch, 2012). Even if we assume that only 1 per 1000 of these potential interactions are biologically relevant, the number to be characterized would be 116, a task likely to consume the lifetime of most laboratories. In reality, of course, we must consider far more proteins and their millions of potential interactions. A way to circumvent this bad news, is to study groups of proteins as interacting single pathway modules (e.g. Fig. 3); correspondingly, the number of potential interactions precipitously declines (Koch, 2012). In this way, systematic analysis of virus-corrupted host cell targets should more easily identify dysregulated host cell networks relevant to viral-implicated tumorigenesis (Rozenblatt-Rosen et al., 2012).

We had every reason to initially assume that either single or co-targeted small molecule inhibition of the EGFR→ERK pathway would result in the complete rescue of SMG pathology (Little et al., 2011; Melnick et al., 2011; Poulidakos and Solit, 2011; Sturm et al., 2010). This proved not to be the case (Fig. 2). To be sure, there was a preclusion of progressive pathogenesis (stability, if you will), even in the continued presence of active CMV. This phenomenon has recently been termed diseases tolerance, i.e. the reduction of the negative impact of an infection on host fitness without directly affecting the pathogen (Medzhitov et al., 2012). Here, specifically, small molecule inhibitors “protected” the SMGs from further destructive pathogenesis independently of CMV load (Fig. 2). All this notwithstanding, failure to rescue SMG pathology suggested to us that other mediators whose signals converge downstream on the ERK pathway remain functional; even in the presence of the highest nontoxic dose of U0126 (an inhibitor of MEK-mediated ERK phosphorylation), pERK protein was undiminished (Fig. 2).

Recently, Wilson et al. (2012) presented convincing evidence that resistance to inhibitors of “oncogenic” kinase (e.g. gefitinib) results from an increase in the ligand levels of alternative pathways that share cell proliferation and survival effectors (ERK and PI3K), i.e. they share similar signaling outputs. Here we present data which supports this proposition. Namely, there is a highly significant upregulation of ligands for the FGR, IL-6R and TNFR signaling pathways (Table 1; Fig. 4), all of which converge upon the Raf/MEK/ERK amplifier module (Fig. 3). These findings are clearly expositive of the failed attempt to simply inhibit EGFR-initiated, MEK mediated, ERK phosphorylation and effect complete rescue of the SMG explants (Fig. 2). It is interesting to note that all relevant ligands (AREG, FGFR, IL-6, TNF-α) are immunolocalized to the abnormally stroma of the CMV-infected SMGs, as is downstream pERK (Figs. 1, 4). This highlights the importance of the stromal microenvironment to progressive pathogenesis, regardless of the degree to which stromal paracrine stimulation participates in the epithelial pathogenesis (Hanahan and Weinberg, 2011; Pietras and Ostman, 2010). Indeed, FG and IL-6 are both highly expressed by tumor-associated fibroblasts in a variety of tumor types (Bhowmick et al., 2004), and here they are relatively most important in characterizing the mCMV-induced pathologic phenotype (Fig. 4).

hCMV-mediated overexpression of IL-6 and TNF-α has previously been reported (Zheng et al., 2012). Further, overexpression of the EGFR, FGFR, IL-6R, and TNFR pathways have been seen in human SG-MEC and other solid tumors (Azevedo et al., 2011; Eli et al., 2010; Ett et al., 2012; Leivo et al., 2005; Mocellin et al., 2005). All of these pathways modulate cell proliferation and cell survival. Untoward upregulation of these particular multifunctional pathways mimics what we and others have shown in normal SG organogenesis (Jaskoll and Melnick, 1999; Jaskoll et al., 2002, 2004; Kashimoto et al., 2000; Koyama et al., 2003; Melnick and Jaskoll, 2000; Melnick et al., 2001a,b, c). Drawing on the evermore apparent parallels between organogenesis and tumorigenesis (e.g. Becker et al., 2012), it should be noted that the EGFR, FGFR, IL-6R and TNFR pathways are not likely to be functionally independent (Jaskoll et al., 2002, 2004; Melnick et al., 2001a,c), but rather part of a larger network whose operational hub is NF-κB (Melnick and Jaskoll, 2000; Melnick et al., 2001b; Fig. 3). This has been proffered for human tumors as well (Karin et al., 2002). Thus, it is becoming increasingly apparent that shared embryonic and tumor genetic signatures may be prognostically important (Becker et al., 2012).

Conclusion

CMV is a principle element in the multifactorial causation of human salivary gland mucoepidermoid carcinoma. Despite the well-documented overexpression of the EGFR→ERK signaling pathway in SG-MEC, there has been little clinical success with inhibition strategies. It has been proposed that failed inhibition results from an increase in the ligand levels of alternative pathways that share cell proliferation and survival effectors (ERK, PI3K). In support of this proposition, we present mouse model evidence of a highly significant upregulation of ligands for the FGR, IL-6R and TNFR signaling pathways, all of which converge upon the Raf/MEK/ERK amplifier module. These findings are clearly expositive of the failed attempt to simply inhibit EGFR-initiated, MEK-mediated, ERK phosphorylation and effect complete rescue. Here we model a potential solution that obviates progressive pathogenesis and effects complete SG rescue (regression), namely the concurrent inhibition of ERK phosphorylation (U0126) and CMV replication (acyclovir).

Conflict of interests

The authors declare that there are no conflicts of interest.

List of abbreviations

AREG amphiregulin
CMV cytomegalovirus
CONT control
CRTCl CREB-regulated transcription coactivator 1
DAPI-4′,6 Diamidino-2-phenylindole, dihydrochloride
Fig. 5. mCMV-replication is essential for progressive pathogenesis and pERK expression in NB+ 14 SMGs. A–C. Control SMGs. Control SMGs exhibit a normal ductal and acinar epithelia embedded in a fibromyxoid stroma consisting of stellate to ovoid fibroblasts. A, inset. High magnification of stellate fibroblasts. Note the absence of immunodetectable pERK (B) and β-galactosidase staining (C) in controls. D–F. mCMV-infected SMGs. With mCMV infection, abnormal epithelia and stroma, as well as increased immunodetectable pERK (compare E to B), are seen; β-galactosidase-stained virus is seen throughout abnormal stroma and, to a lesser extent, in epithelia (compare F to C). D, inset. High magnification of viral CPE in stroma. G–I. mCMV-infected SMGs treated with acyclovir beginning on day 6 (CMV+D6Ac). With acyclovir-treatment, there is a marked improvement in epithelial and stromal morphology compared to untreated, mCMV-infected SMGs (compare G to D) and little β-galactosidase-stained virus (arrowheads) (I). However, ductal and acini exhibit a pseudo-stratified, hyperplastic epithelium surrounding lumina rather than the cuboidal epithelium seen in controls (compare G to A). pERK immunolocalization is similar to that seen in controls (compare H to B) and markedly less than in mCMV-infected SMGs (compare H to E). G inset. High magnification of stroma showing normal stellate fibroblasts and the absence of viral CPE. J–L. mCMV-infected SMGs treated with U0126 + acyclovir beginning on day 6 (CMV+D6U+D6 ACY). The addition of U0126 to acyclovir-treated SMGs results in normal epithelial and stromal morphology (compare J to A, D), the absence of β-galactosidase-stained virus (compare L to C), and pERK immunolocalization resembling control (compare K to B). J inset. High magnification showing normal stellate fibroblast and absence of viral CPE in stroma. Bar: A, C, D, F, G, I, J, L — 60 μm; B, E, H, K — 50 μm; insets — 30 μm.
ERK extracellular signal-regulated protein kinases 1 and 2 (ERK1/2)
EGFR epidermal growth factor receptor
GEF gefitinib
hCMV human cytomegalovirus
mCMV mouse cytomegalovirus
MEK mitogen-activated protein kinase
NB newborn
NFA negative feedback amplifier
pERK phosphorylated ERK1/2
PFU plaque forming units
PNN Probabilistic neural network analysis
qRT-PCR quantitative RT-PCR
Raf rapidly accelerated fibrosarcoma oncogene
Ras rat sarcoma viral oncogene
RTK receptor tyrosine kinase
SG salivary gland
SMG salivary gland
SOS guanine nucleotide exchange factors
TK tyrosine kinase

Acknowledgments

We would like to thank Dr. Edward Mocarski for his generous gift of mCMV. This research was supported by the Oral Biology Fund of the University of Southern California.

References


Proceedings of the National Academy of Sciences of the United States of America 96, 10881–10886.